30 results about "PBR322" patented technology

The invention discloses a CRISPR/Cas9-mediated large DNA fragment assembling method. Specifically, the invention provides a nucleic acid construct capable of carrying out constitutive expression of Cas9 in yeast; the nucleic acid construct contains a yeast Tef1 promoter operationally connected with a Cas9 gene, a replication origin from pBR322 and a screening mark thereof, and a replication region from CEN6ARS4 and a screening mark thereof; and the nucleic acid construct is in the form of single-copy replication in the yeast and in the form of high-copy replication in Escherichia coli. The invention also provides a nucleic acid construct capable of carrying out constitutive expression of sgRNA in yeast, a nucleic acid construct used as a receptor vector and a DNA assembling method. According to the invention, two or more to-be-assembled large DNA fragments are successfully assembled in microzyme to form a large plasmid in one shot; so low-efficiency in-vitro digestion recovery, genetic transformation and the like of large DNA fragments are avoided, and the method provided by the invention is more convenient and efficient compared with traditional methods.

The invention discloses a biological mothballing system suitable for synechococcus elongatus, and a construction method and application of the biological mothballing system. The construction method comprises the steps that a virulent gene sepT2, an antitoxic gene sepA2 and an iron-deficiency inducible promoter PisiAB are obtained from the synechococcus elongatus 7942, and a promoter PpsbA2 is obtained from synechocystis 6803; a terminator Trbcl is obtained from integrative plasmid pBA3031 through amplification; pBR322 is taken as a carrier, the virulent gene sepT2 is expressed with the iron-deficiency inducible promoter PisiAB, and the terminator Trbcl is used for terminating transcription; and the antitoxic gene sepA2 is expressed with the promoter PpsbA2, and plasmid is constructed and transferred into the synechococcus elongatus. According to the system, the synechococcus elongatus grows normally under the non-inducing situation and rapidly dies after being induced. The important theoretical and practical significance for development and optimization of the biological mothballing system of the synechococcus elongatus is achieved, and reference is also provided for solving the bio-safety problem of other cyanobacteria.

The invention discloses a fowl type-4 adenovirus vector for target infection on mammalian cells and application of the fowl type-4 adenovirus vector. The vector comprises a genome sequence of a fowl type-4 adenovirus, a replication origin nucleotide sequence of pBR322 and a kanamycin resistance nucleotide sequence, wherein a fiber nucleotide sequence in the genome sequence is artificially transformed, including inserting an RGD4C short peptide nucleotide sequence into a Knob region of a fiber gene, and/or the Knob region of the fiber gene is replaced by a nucleotide sequence of human type-35 adenovirus fiber Knob. The transformed fowl type-4 adenovirus vector disclosed by the invention is capable of improving the infection efficiency on the mammalian cells, and can be adopted to prepare recombinant vaccines or gene treatment kits of mammals.

A heat-resistant NDV live vaccine vector system includes a transcription plasmid, three helper plasmids, and host cells. The transcription plasmid is constructed by through cloning complete genomic cDNA of a heat-resistant NDV vaccine strain to a pBR322 vector. The three helper plasmids are constructed by cloning sequences coding nucleoprotein (NP), phosphoprotein, large polymerase protein of a heat-resistant NDV vaccine strain respectively to pcDNA3.1 vectors. A recombinant NDV artificially obtained by cotransfacting host cells with the transcription plasmid and the three helper plasmids shows heat-resistance.

The invention relates to the technical field of reverse genetic manipulation, and discloses a rescuing method of a gene VII type Newcastle disease virus subjected to codon replacement. The method comprises the steps: respectively cloning the NP, P and L genes of the Newcastle disease virus and the DE3 gene for expressing the T7 RNA polymerase into a pXJ40 vector to obtain plasmids pXJ40-NP, pXJ40-P, pXJ40-L and pXJ40-DE3; cloning the whole genome cDNA of the Newcastle disease virus into a pBR322 plasmid to obtain pBR322-DHN3; replacing part of codons in an NP gene coding region with codons with the highest use frequency in a unified manner, and replacing the codons with pBR322-DHN3 plasmids to form new plasmids pBR322-mNPDHN3; and co-transfecting bHK-21 cells by adopting the five plasmidsso that the rescued virus rDHN3-mNP is obtained. The method provided by the invention is more beneficial to virus rescue and virus pathogenic mechanism research.

The invention relates to the technical field of biology, and discloses an avian pathogenicity escherichia coli type VI secretion system clpV gene deleted strain as well as a construction method and anapplication thereof, which are used for researching, preventing and controlling pathogenesis of avian pathogenicity escherichia coli. And successfully a clpV gene deleted strain of the APEC TW-XM strain is constructed by using a Red homologous recombination system to obtain the deleted strain TW-XM clpV. And the clpV gene is cloned into an expression vector pBR322, and transformed into a deletedstrain TW-XM delta clpV to obtain a corresponding gene complementary strain TW-XMC delta clpV. A mouse infected animal model is constructed by intraperitoneal injection of escherichia coli, and it isfound through detection that the bacterial load of brain, blood and lung tissue and the expression of meningitis related inflammatory factor mRNA in the brain tissue are obviously reduced. It demonstrates that clpV is closely related to APEC pathogenicity.

The invention discloses a modified plasmid replicon and application thereof. The modified plasmid replicon is a mutant of a classic low-copy replicon pSC101 with the 93rd glutamic acid of RepA protein mutating into proline, and the codon encoding the proline is CCG. Plasmids carrying the artificially-modified plasmid replicon (pSC101-RepA-E93P), after being replicated in escherichia coli, can achieve an in-vitro extraction yield, which is about 12 times of that of plasmids carrying a wild type replicon of pSC101 and about twice of that of plasmids of pUC57 carrying CorEI/pMB1/pBR322-type high-copy replicons. Meanwhile, in the Escherichia coli, the plasmids carrying the modified plasmid replicon can achieve replication almost at the same proportion with the plasmids carrying the CorEI/pMB1/pBR322-type high-copy replicons.

The invention relates to an insertional inactivation type cloning vector pATC 4185 with ampicillin and tetracycline resistant genes. The vector is obtained by the following steps: removing the Rop gene on pBR322 by double digestion method, filling in the end and looping internally. pATC4185 not only preserves the insertional inactivation screening mark of pBR322, but also has smaller molecular weight and higher stability, and the plasmid copy number increases more than three times, and the product is convenient for gene clone operation with higher operating efficiency. The product can replace pBR322 plasmid which is widely used at present, and is used as a general high efficiency cloning vector.

The invention discloses an avian 4-type adenovirus vector, a construction method and an attenuated live vaccine and application of the avian 4-type adenovirus vector. The avian 4-type adenovirus vector comprises a replication origin nucleic acid sequence of pBR322 plasmid, a nucleic acid sequence of a kanamycin resistance gene and a genomic sequence of avian 4-type adenovirus; and in the genomic sequence of the avian 4-type adenovirus, genes ORF1, ORF1B, ORF2, ORF19A and GAM-1 are all inactivated. The avian 4-type adenovirus obtained by rescuing after the linearized avian 4-type adenovirus vector transfects cells is used as the attenuated live vaccine, and the attenuated live vaccine has the advantages of no pathogenicity, high safety and good immune protection effect, and can be used for preparing drugs for preventing diseases caused by avian adenovirus infection.

The invention relates to a method for preparing rebaudioside D by fermentation catalysis of bacillus subtilis, which is characterized by comprising the following steps: (1) inoculating glycosyl transferase UGT76G1 and AtSUSY genes to a PBR322 plasmid vector, guiding into the bacillus subtilis, inoculating into an LB culture medium, and culturing for 20-24 hours at the temperature of 30-37 DEG C and the speed of 100-250 rpm; (2) inoculating into a seed tank according to the inoculation amount of 1%-10%, and culturing for 20-24 hours at the temperature of 30-37 DEG C at the speed of 200-400 rpm and the ventilation ratio of 0.1-1 V/V.min; (3) inoculating into a fermentation tank according to the volume ratio of 1%-10%, and culturing for 48-72 hours under the conditions that the speed is 200-1000 rpm, the ventilation ratio is 0.1-2 V/V.min, the temperature is 30-37 DEG C and the pH value is 6-8; (4) carrying out ultrafiltration on the fermentation liquor by adopting a ceramic membrane, resuspending bacteria, carrying out high-pressure homogeneous crushing, and carrying out ultrafiltration on the crushed liquor by adopting the ceramic membrane to obtain crude enzyme liquor; and (5) mixing stevioside, uridine diphosphate glucose, a Tris-HCl buffer solution and the crude enzyme solution according to a mass ratio of (5-10): (1-5): (40-60): (5-20), and reacting at 25-40 DEG C for 12-48 hours. The method has the advantages that two crude enzymes are obtained through one-time fermentation, the cost is low, and the conversion rate of rebaudioside D reaches 88-90 g/L.

The invention relates to an insertional inactivation type cloning vector pAT 3733 with ampicillin and tetracycline resistant genes. The vector is obtained by the following steps: removing the Rop gene on pBR322 by double digestion method, filling in the end and looping internally. pAT3733 not only preserves the insertional inactivation screening mark of pBR322, but also has smaller molecular weight and higher stability, and the plasmid copy number increases more than three times, and the product is convenient for gene clone operation with higher operating efficiency. The product can replace pBR322 plasmid which is widely used at present, and is used as a general high efficiency cloning vector.

The invention relates to construction and application of SHIV (simian/human immunodeficiency virus) infectious clone. Firstly, the overall length genome of a virulent strain SHIV-KB9 embedded with a B subtype env gene is cloned to a low copy number carrier pBR322, the obtained plasmid SHIV-KB9/pBR322 is taken as a genome skeleton, the env gene of Chinese main prevalent strain CRF08_BC of HIV-1 is used for substituting for corresponding gene segments so as to obtain the infectious clone SHIV-KBQJ-12, the replacing env gene is from the infectious clone strain QJ001 of HIV-1CRF08_BC and comprises the whole intracellular region, a transmembrane region and part of an extracellular region of gp120 and gp41, and the position of the replacing env gene, corresponding to the position of the nucleotide of a standard reference strain HXB2, is 6103-8249. The construction is simple and convenient to operate, has high success rate, can obtain the infectious clone in a short time, and can be used for establishing an SHIV/Chinese rhesus infection model.